February 22 - 24, 2010, The Hyatt at Bellevue, Philadelphia, PA
Register by January 29, 2010 and receive up to $1,945 off!
Download the Brochure
Visit the Download Center to access related podcasts and other useful resources.
The 9th Lean Six Sigma for Pharmaceutical, Biotech, and Medical Device Excellence conference will be the only gathering for lean six sigma, continuous improvement, and operational excellence professionals in 2010. We are combining the West Coast conference into the February event in Philadelphia.
Become a Pharma IQ Member and receive our weekly newsletter!
Learn more about sponsor & exhibit opportunities
Countdown to Event
Mark Your Calendar
Tell a Colleague
With more and more companies embracing the Six Sigma philosophies and tools, new questions have arisen, especially from the areas where new processes are needed. DFSS has been identified as a vital strategy to create and maximize value for the organization’s performance and customer satisfaction. In this master class, we will walk you through the key principles and tools for DFSS to achieve maximum results.
What will be Covered:
How will you benefit:
Workshop Leader:
Jeff Slutsky Global Director of DFSS Bausch&Lomb Inc.
Back to Top
No matter where you are in your Lean Six Sigma journey, addressing the needs of the people to sustain a program or a project implementation is difficult. While some of us are better than others, no one has completely mastered this arena, where there is always room for improvement. As a panel workshop, we will review the various approaches, success stories, failure anecdotes, and reflect on how these essons can be applied to our own organizations.
What will be covered:
Panel Workshop Leaders:
Lyndi Gillespie Operational Excellence Expert, Global Manufacturing & Supply Biopharm GlaxoSmithKline
Deepa Kumar Operational Excellence Expert, Global Manufacturing & Supply Biopharm GlaxoSmithKline
Kimberly Palladino LSS MBB, Biopharm R&D GlaxoSmithKline
Six Sigma projects, just as any other project in a company, have economic value, downside risk and upside potential. Such projects may have upfront investments, require some time before benefits can be achieved and often have technical risks. The value of a project is a function of these costs, timelines, risks and anticipated benefits. However, none of these can be determined in a precise fashion before the project can be undertaken. All of these are uncertain, but they often provide flexibility to change course in the future. Decision Options is a holistic method to calculate economic value when uncertainties and decision flexibilities are present. Using economic value and associated downside risk and upside potential, companies can make better selection, design and management decisions of Six Sigma projects. The workshop will focus on demonstrating these tools and techniques through case studies.
Workshop Leaders:
Gill Eapen CFA Founder and Managing Principal Decision Options, LLC
Jennifer Miller Executive Director Pfizer
Considerable progress has been made in the use of Lean Six Sigma to improve the performance of life science industries. Many are now asking what’s next and what can be done after implementing Lean Six Sigma? Just as business improvement approaches have grown and evolved over the last 100 years, so is Lean Six Sigma. This workshop addresses recent developments in the use of Lean Six Sigma and how you can measure, evaluate, benchmark and update the approach used by your organization. The session will be highly interactive, using a mixture of material presentations, discussions and responses to participants’ questions.
Ron Snee President Snee Associates, LLC.
Over the past decade, many of the leading manufacturers of pharmaceuticals and biologics have applied Lean principles to their manufacturing processes, resulting in dramatic improvements in cycle times, quality, and productivity. To realize the full benefits that Lean can offer however, requires applying the same principles in the lab, resulting in dramatically reduced cycle times, improved lab capacity, and streamlined process flows, all while increasing compliance.
Thomas Bertels Partner Valeocon Management Consulting
Thomas is responsible for Valeocon's practice in the United States and leading the firm's life sciences practice. He is a widely recognized expert on Operational Excellence and has worked extensively with leading firms such as Pfizer, Novartis, J&J, and Lonza.
[ Register Now ]